Treatment for Oligometastatic Disease

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Oligometastatic Disease
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers learn if a new cancer treatment is effective and safe.

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 5 years

3 Years
Feasibility of SRS/SBRT in patients with metastatic disease at initial presentation
5 years
Analysis of patterns of failure post-SRS
Local control of metastatic sites
Local control of primary site
Overall survival
Quality of life (as measured by FACT surveys)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

0 Treatment Group

44 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Steven BurtonLead Sponsor
3 Previous Clinical Trials
205 Total Patients Enrolled
Gregory J Kubicek, MDPrincipal InvestigatorUniversity of Pittsburgh

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
"The person has a solid malignancy that has been diagnosed through pathology (either through a histology or cytology examination) within 8 weeks of registration.
Eligible disease sites include the following: the skin, mucous membranes, and the upper respiratory tract.
You have breasts.\n
The prostate gland is present.
GI cancers, including colorectal, anal, esophageal, pancreas, and gastric cancers (excluding colon cancer with resectable liver-only lesions), are associated with a high incidence of liver metastases.
You have a tumour in the head and neck.
is an uncommon cancer that arises from connective tissues such as muscle, fat, and bone
You have skin (melanoma and squamous cell carcinoma).